FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 360 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Comme louer son affaire en compagnie de tacht mahometane? (2023) August 13, 2023 Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer August 13, 2020 Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells December 14, 2018 Are Cancer Patients Getting the Opioids They Need to Control Pain? September 16, 2020 Load more HOT NEWS Mother and Daughter Graduate Nursing Masters Programs Together After Breast Cancer... Transforming optimism: finding new ways to treat rare cancers FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2-positive Gastric Adenocarcinomas News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and...
